Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis
ConclusionThe risk of flare/relapse/exacerbation in AI-IMD patients is found to be minimal, especially with vector-based vaccines. Vaccination against COVID-19 is recommended in this population.
Source: European Journal of Medical Research - Category: Research Source Type: research
More News: Autoimmune Disease | Brain | Covid Vaccine | COVID-19 | Dermatology | Hematology | Neurology | Neuroscience | Research | SARS | Science | Skin | Statistics | Study | Urology & Nephrology | Vaccines